Bayer AG (OTCPK:BAYRY +3%) moves higher after announcing its partner Janssen Research &...

Bayer AG (OTCPK:BAYRY +3%) moves higher after announcing its partner Janssen Research & Development has submitted a supplemental new drug application to the FDA for its oral anticoagulant Xarelto, also known as rivaroxaban, in combination with standard antiplatelet therapy to reduce the risk of cardiovascular events in patients with acute coronary syndrome.